News

Filter

Current filters:

GlaxoSmithKlineRituxan

1 to 9 of 33 results

Pipeline innovation bodes well for systemic lupus erythematosus market

18-02-2014

While the systemic lupus erythematosus (SLE) treatment market is predominantly limited to GlaxoSmithKline’s…

AmgenAnti-Arthritics/RheumaticsBenlystaGlaxoSmithKlineImmuPharmaLupuzorLymphoCideMarkets & MarketingPharmaceuticalRituxanRoche

US FDA warns of hepatitis B reactivation risk with Arzerra and Rituxan

US FDA warns of hepatitis B reactivation risk with Arzerra and Rituxan

26-09-2013

The US Food and Drug Administration has approved changes to the prescribing information of the immune-suppressing…

Anti-Arthritics/RheumaticsArzerraBiogen IdecGlaxoSmithKlineNorth AmericaOncologyPharmaceuticalRegulationRituxanRoche

EU5 rheumatologits rate Rituxan and Benlysta for Lupus

12-08-2013

Rheumatologists in the top European nations ( EU5) countries (France, Germany, Italy, Spain, UK) give…

Anti-Arthritics/RheumaticsBenlystaBiogen IdecBristol-Myers SquibbEuropeGlaxoSmithKlineMarkets & MarketingOrenciaPharmaceuticalRituxanRoche

Non-Hodgkins lymphoma drug market set to more than double by 2019

05-05-2011

Driven by the launches of premium-priced therapies, the non-Hodgkin’s lymphoma drug market will…

ArzerraGlaxoSmithKlineMarkets & MarketingOncologyPharmaceuticalRituxanrituximabRoche

GlaxoSmithKline/HGS's Benlysta will push SLE drug market to more than $1.6 billion in 2019

10-08-2010

Driven primarily by the launch and uptake of Human Genome Sciences and GlaxoSmithKline's Benlysta (belimumab),…

Anti-Arthritics/RheumaticsBenlystaGlaxoSmithKlineHuman Genome SciencesMabTheraMarkets & MarketingPharmaceuticalRituxan

Genentech and Biogen sue GlaxoSmithKline and Genmab over Arzerra patent

26-03-2010

US biotechnology giant Genentech, a wholly-owned subsidiary of Switzerland’s Roche, and Biogen Idec…

ArzerraBiogen IdecBiotechnologyGenentechGenmabGlaxoSmithKlineOncologyPatentsPharmaceuticalRituxanRoche

1 to 9 of 33 results

COMPANY SPOTLIGHT

Menarini

Back to top